摘要
目的:探讨灯盏花素微丸在大鼠体内药动学规律,并进行相对生物利用度研究。方法:采用大鼠双周期交叉试验设计,对大鼠口服灯盏花素微丸胶囊和灯盏花素片的动力学参数进行比较。结果:灯盏花素微丸胶囊和灯盏花素片的主要药代参数:Tpeak分别为(5.50±1.05)h和(4.17±0.41)h;t1/2ke分别为(2.97±0.17)h和(2.04±0.74)h;Cmax分别为(1.50±0.52)μg/mL和(0.48±0.18)μg/m:;AUC0～t分别为(6.09±0.80)μg*h/mL和(2.00±0.40)μg*h/mL。灯盏花素微丸胶囊和灯盏花素片的Tpeak和t1/2ke具有明显统计学差异(P<0.05),灯盏花素微丸胶囊相对于灯盏花素片的生物利用度为303.92%。结论灯盏花素微丸胶囊的相对生物利用度明显高于灯盏花素片。
Objective：To investigate the pharmacokinetics and the relative bioavailability of breviscapine pellet capsules in rats.Methods：The cross-over design（two periods） was employed.The pharmacokinetics parameters were compared after rats were administrated a single dose of the oral breviscapine pellet capsules and breviscapine tablets.Resutlts：The main pharmacokinetics parameters of breviscapine pellet capsules and breviscapine tablets as follows： Tpeak were 5.50±1.05h and 4.17±0.41h;t1/2ke were 2.97±0.17h and 2.04±0.74 h;Cmax were 1.50±0.52μg/mL and 0.48±0.18μg/mL;AUC0～t were 6.09±0.80μg＊h/ml and 2.00±0.40 μg＊h/mL,respectively.The difference was significant between breviscapine pellet capsules and breviscapine tablets in Tpeak and t1/2ke（P0.05）and the bioavailability of breviscapine pellet capsules relative to breviscapine tablets was 303.92%.Conclusion：The relative bioavailability of breviscapine pellet capsules was higher than that of breviscapine tablets.
出处
《云南中医学院学报》
2010年第6期55-57,65,共4页
Journal of Yunnan University of Traditional Chinese Medicine
基金
云南省科技厅新药研究开发专项计划资助项目(2000XY10)
